Stephen Wall, MD
Internal Medicine · Springfield
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Mckenzie Physician Services LLC · 48 clinicians in this group
Hospitals listed: Mckenzie-Willamette Medical Center · Mercy Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Wall’s office at (541) 744-6172 to ask if they take your plan before you enroll.
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Mckenzie-Willamette Medical CenterSpringfield, ORAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Quorum Health Corporation, which runs 39 hospitals in 23 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 4 of 5 starsNo measure marked better or worse than the national rate
- Mercy Medical CenterRoseburg, ORAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 3 of 5 · 56% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.232, Oct 2024 – Sep 2025
See every measure and the patient survey for Mckenzie-Willamette Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 1 worse of 8 measures. Safety: 0 better, 7 the same, 0 worse of 7 measures. Readmissions: 1 better, 7 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.48 (0.44 to 2.52) · 594 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.89 (0.51 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 183.83 (122.08 to 245.58) · 29 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 46 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 14.5 · 56 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13 · 54 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.6 · 119 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.3 · 115 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.6 · 87 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.1 · 2,021 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.23 (0.02 to 0.45) · 2,556 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.32 (0.12 to 0.53) · 2,556 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.05 (0.88 to 5.22) · 1,129 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.43 (0 to 3.03) · 734 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.53 (1.02 to 4.04) · 1,101 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.57 (3.84 to 17.31) · 755 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 3.75 (0.07 to 7.42) · 733 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.7 (0.2 to 3.21) · 263 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 1.3) · 1,528 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 200 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.963 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.904 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.297 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.2 · 188 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.7 · 353 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.8 · 91 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -20.6 · 144 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -7.5 · 135 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 351 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.6 · 175 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.9 · 41 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.8 · 116 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.3 (9.9 to 17.9) · 166 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.6 to 1.2) · 298 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,356 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 72% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Mercy Medical Center
Behind the star rating — Deaths: 0 better, 5 the same, 1 worse of 6 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 4 better, 3 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.232 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.99 (0 to 2.05) · 350 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.9 (0.47 to 1.32) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 11.8 · 84 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.6 · 147 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 13.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.2 · 224 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.4 · 191 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.3 · 1,684 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 2,762 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.46) · 2,684 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.88 (0.48 to 5.28) · 450 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.66 (0 to 3.38) · 54 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.18 (0.5 to 3.86) · 423 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.97 (1.35 to 20.59) · 56 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.04 (0.78 to 9.3) · 45 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.7 (0.2 to 3.21) · 104 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.31 (0 to 1.26) · 2,236 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.498 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.3 · 184 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.4 · 359 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -17.8 · 126 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13 · 271 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -35.1 · 217 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.2 · 353 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 140 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.5 (8.9 to 15) · 1,646 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.6 to 1.2) · 368 cases | No different | Jan 2024 – Dec 2024 |
What patients said (622 patients answered, 19% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 3 |
| Room was "always" clean | 67% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 56% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$140,901
Medicare paid this office $140,901 for 1,027 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 117 | $36,380 | $311 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 191 | $25,478 | $130 |
| Return visit (30+ min) | 169 | $15,995 | $84 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 117 | $6,314 | $27 |
| New patient visit (45+ min) | 71 | $6,064 | $85 |
See all 28 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 117 | $36,380 | $311 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 191 | $25,478 | $130 |
| Return visit (30+ min) | 169 | $15,995 | $84 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 117 | $6,314 | $27 |
| New patient visit (45+ min) | 71 | $6,064 | $85 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 125 | $5,885 | $47 |
| Long return visit (40+ min) | 33 | $4,263 | $112 |
| New patient visit (60+ min) | 24 | $3,725 | $155 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 76 | $3,635 | $48 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 22 | $3,485 | $158 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 480 | $3,245 | $6 |
| Injection, regadenoson, 0.1 mg | 103 | $2,276 | None |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $1,556 | $130 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 28 | $1,120 | $40 |
| External shock to heart to regulate heart beat | 16 | $1,051 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,014 | $56 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 94 | $973 | $10 |
| Programming of dual lead pacemaker system | 14 | $882 | $59 |
| Ultrasound of heart with probe in esophagus, with report | 11 | $848 | $77 |
| Short return visit (20+ min) | 14 | $836 | $56 |
| Ultrasound of heart blood flow, valves and chambers | 17 | $650 | $38 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 25 | $419 | $17 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 18 | $324 | $18 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 31 | $283 | $9 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 25 | $208 | $8 |
| Injection, aminophyllin, up to 250 mg | 12 | $88 | None |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 13 | $68 | $5 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 20 | $48 | $2 |
Procedures Medicare counted
| Pacemaker insertion or repair | 12 | More than 63% of doctors who do this |
Who their Medicare patients are
1,027 Original Medicare patients in 2024. Average age 73 · Under 65 11% · 85 and older 11% · Women 50% · Also on Medicaid 18% · Health risk score 1.35. At or below the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 75% · Coronary heart disease 35% · Atrial fibrillation 31% · Diabetes 30% · Heart failure 28% · Chronic kidney disease 28% · Depression 22% · COPD 19% · Cancer 14% · Stroke 9% · Dementia 7%.
The office billed $701,230, Medicare allowed $193,349 and paid $140,901; for 2,577 services of 64 kinds; $2,364 of it was for drugs given in the office and $138,537 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,027 | 2,577 | 73 | 1.35 | $701,230 | $140,901 |
| 2023 | 982 | 2,637 | 74 | 1.35 | $705,574 | $166,585 |
| 2022 | 605 | 1,504 | 74 | 1.35 | $401,719 | $99,265 |
| 2021 | 284 | 465 | 72 | 1.39 | $87,160 | $24,655 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 32 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 227 | $32,056 | $139 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 103 | $27,831 | $270 |
| Return visit (30+ min) | 189 | $19,507 | $87 |
| Injection, regadenoson, 0.1 mg | 92 | $15,309 | None |
| New patient visit (45+ min) | 91 | $10,602 | $117 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 103 | $5,547 | $27 |
| Long return visit (40+ min) | 38 | $5,440 | $116 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 109 | $5,117 | $46 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 101 | $4,806 | $48 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 26 | $4,540 | $175 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 388 | $2,656 | $6 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 49 | $2,608 | $48 |
| New patient visit (60+ min) | 14 | $2,350 | $168 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 11 | $2,263 | $206 |
| Short return visit (20+ min) | 34 | $1,797 | $53 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring and review and report by health care professional | 15 | $1,790 | $112 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $1,464 | $113 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 120 | $1,384 | $10 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,376 | $60 |
| External shock to heart to regulate heart beat | 14 | $1,221 | $81 |
| Ultrasound of heart with probe in esophagus, with report | 13 | $1,159 | $77 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,108 | $85 |
| Programming of dual lead pacemaker system | 16 | $950 | $59 |
| Ultrasound of heart blood flow, valves and chambers | 21 | $831 | $40 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 35 | $622 | $17 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 43 | $418 | $9 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 22 | $404 | $18 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 34 | $295 | $8 |
| Ultrasound of heart, follow-up | 14 | $252 | $18 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 18 | $105 | $5 |
| Injection, aminophyllin, up to 250 mg | 12 | $82 | None |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 22 | $55 | $2 |
2022: 23 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 120 | $17,736 | $142 |
| Return visit (30+ min) | 111 | $11,950 | $96 |
| New patient visit (45+ min) | 84 | $8,672 | $103 |
| Injection, regadenoson, 0.1 mg | 42 | $7,893 | None |
| Long return visit (40+ min) | 61 | $7,728 | $112 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 90 | $4,536 | $49 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 11 | $4,253 | $387 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 26 | $4,191 | $161 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 48 | $3,147 | $66 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 57 | $2,967 | $51 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 49 | $2,586 | $26 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,402 | $141 |
| Short return visit (20+ min) | 29 | $2,075 | $67 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $1,868 | $67 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 34 | $1,546 | $45 |
| Ultrasound of heart blood flow, valves and chambers | 21 | $838 | $40 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 138 | $782 | $5 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 66 | $750 | $10 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 23 | $426 | $19 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 31 | $312 | $9 |
| Ultrasound of heart, follow-up | 12 | $194 | $15 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 11 | $121 | $10 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 16 | $31 | $2 |
2021: 9 services
| Long return visit (40+ min) | 34 | $4,777 | $141 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 30 | $4,512 | $150 |
| New patient visit (45+ min) | 19 | $2,469 | $130 |
| Return visit (30+ min) | 14 | $1,506 | $100 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 29 | $1,490 | $51 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 179 | $1,223 | $6 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 11 | $633 | $58 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 23 | $257 | $11 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 13 | $126 | $10 |
Medicaid work
$38,180 in 2024
Medicaid paid $38,180 for 1,704 billed services this clinician did in 2024, up to 114 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 308 | $29,650 |
| New patient visit (45+ min) | 32 | $3,760 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 487 | $2,522 |
| Return visit (30+ min) | 27 | $1,120 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 61 | $625 |
| CARDIOVASCULAR STRESS TEST | 14 | $504 |
| TOBACCO NON-USER | 192 | $0 |
| Medication list documented in medical record (COA) | 51 | $0 |
| Review of all medications by a prescribing practitioner or clinical pharmacist (such as, prescriptions, OTCs, herbal therapies and supplements) documented in the medical record (COA) | 51 | $0 |
| BODY MASS INDEX DOCD | 257 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 122 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 85 | $0 |
| 2024 | 1,704 | 13 | 114 | $38,180 |
| 2023 | 2,488 | 12 | 166 | $44,463 |
| 2022 | 1,094 | 5 | 156 | $31,861 |
| 2021 | 495 | 4 | 111 | $10,952 |
See the largest Medicaid services in earlier years
2023
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 356 | $32,942 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 933 | $4,781 |
| New patient visit (45+ min) | 44 | $4,367 |
| Return visit (30+ min) | 41 | $1,835 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 67 | $539 |
| TOBACCO NON-USER | 163 | $0 |
| Medication list documented in medical record (COA) | 216 | $0 |
| Review of all medications by a prescribing practitioner or clinical pharmacist (such as, prescriptions, OTCs, herbal therapies and supplements) documented in the medical record (COA) | 216 | $0 |
| BODY MASS INDEX DOCD | 203 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 137 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 99 | $0 |
| Most recent diastolic blood pressure 80-89 mm Hg (HTN, CKD, CAD) (DM) | 13 | $0 |
2022
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 270 | $24,202 |
| New patient visit (45+ min) | 35 | $3,012 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 742 | $2,791 |
| Return visit (30+ min) | 30 | $1,325 |
| CARDIOVASCULAR STRESS TEST | 17 | $532 |
2021
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 69 | $5,763 |
| New patient visit (45+ min) | 31 | $3,132 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 378 | $1,884 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 17 | $173 |
Drugs they prescribed that Part D paid
$1,378,179
Pharmacies billed $1,378,179 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 5,774) in 2024. At or below the middle of the specialty; the typical internal medicine clinician is at 1%.
4,565 generic and fewer than 11 brand-name prescriptions · $1,378,179 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 509 | $659,402 | $1,295 |
| Farxiga | 154 | $154,186 | $1,001 |
| Jardiance | 110 | $119,973 | $1,091 |
| Xarelto | 100 | $118,836 | $1,188 |
| Entresto | 65 | $72,373 | $1,113 |
See all 47 drugs
| Eliquis | 509 | $659,402 | $1,295 |
| Farxiga | 154 | $154,186 | $1,001 |
| Jardiance | 110 | $119,973 | $1,091 |
| Xarelto | 100 | $118,836 | $1,188 |
| Entresto | 65 | $72,373 | $1,113 |
| Repatha Sureclick | 79 | $69,727 | $883 |
| Ozempic | 44 | $45,912 | $1,043 |
| Praluent | 22 | $20,532 | $933 |
| Dapagliflozin | 23 | $9,066 | $394 |
| Rosuvastatin | 578 | $8,788 | $15 |
| Metoprolol | 435 | $6,494 | $15 |
| Valsartan | 131 | $5,423 | $41 |
| Ezetimibe | 154 | $4,982 | $32 |
| Flecainide Acetate | 116 | $4,361 | $38 |
| Atorvastatin | 353 | $4,060 | $12 |
| Spironolactone | 369 | $3,639 | $10 |
| Carvedilol | 271 | $3,128 | $12 |
| Clopidogrel | 166 | $2,889 | $17 |
| Bisoprolol | 90 | $2,555 | $28 |
| Torsemide | 117 | $2,453 | $21 |
| Amlodipine Besylate | 210 | $2,238 | $11 |
| Amiodarone | 117 | $1,856 | $16 |
| Metoprolol | 187 | $1,741 | $9 |
| Diltiazem 24hr Er (Cd) | 75 | $1,709 | $23 |
| Losartan-Hydrochlorothiazide | 60 | $1,333 | $22 |
| Losartan | 136 | $1,290 | $9 |
| Irbesartan | 38 | $1,141 | $30 |
| Olmesartan-Hydrochlorothiazide | 21 | $1,137 | $54 |
| Potassium Chloride | 69 | $1,131 | $16 |
| Furosemide | 177 | $1,111 | $6 |
| Lisinopril | 120 | $1,108 | $9 |
| Verapamil Er | 32 | $985 | $31 |
| Telmisartan | 19 | $807 | $42 |
| Olmesartan Medoxomil | 33 | $794 | $24 |
| Prasugrel | 11 | $743 | $68 |
| Sotalol | 21 | $735 | $35 |
| Digoxin | 14 | $606 | $43 |
| Hydrochlorothiazide | 102 | $585 | $6 |
| Isosorbide Mononitrate Er | 65 | $468 | $7 |
| Famotidine | 22 | $424 | $19 |
| Nitroglycerin | 37 | $421 | $11 |
| Lisinopril-Hydrochlorothiazide | 36 | $366 | $10 |
| Pantoprazole | 16 | $335 | $21 |
| Pravastatin | 19 | $282 | $15 |
| Atenolol | 17 | $216 | $13 |
| Levothyroxine | 11 | $119 | $11 |
| Hydralazine | 17 | $91 | $5 |
Year by year
| 2024 | 5,774 | 889 | 0% (0) | None | $1,378,179 |
| 2023 | 4,313 | 751 | 0% (0) | None | $889,500 |
| 2022 | 2,047 | 446 | 0% (0) | 17% | $358,639 |
| 2021 | 614 | 152 | 0% (0) | 18% | $85,753 |
| 2020 | 563 | 87 | None | 17% | $73,629 |
| 2019 | 462 | 65 | 0% (0) | 19% | $53,011 |
| 2018 | 121 | 38 | 0% (0) | 22% | $10,743 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 41 drugs
| Eliquis | 363 | $449,682 | $1,239 |
| Xarelto | 89 | $127,438 | $1,432 |
| Jardiance | 38 | $54,645 | $1,438 |
| Repatha Sureclick | 52 | $45,616 | $877 |
| Entresto | 35 | $41,186 | $1,177 |
| Farxiga | 37 | $39,451 | $1,066 |
| Praluent | 18 | $15,376 | $854 |
| Rosuvastatin | 416 | $9,941 | $24 |
| Metoprolol | 350 | $8,188 | $23 |
| Flecainide Acetate | 63 | $5,366 | $85 |
| Valsartan | 82 | $4,752 | $58 |
| Atorvastatin | 261 | $4,446 | $17 |
| Bisoprolol | 84 | $3,964 | $47 |
| Diltiazem 24hr Er (Cd) | 68 | $3,656 | $54 |
| Carvedilol | 215 | $3,458 | $16 |
| Amiodarone | 116 | $2,779 | $24 |
| Torsemide | 93 | $2,705 | $29 |
| Spironolactone | 230 | $2,632 | $11 |
| Clopidogrel | 129 | $2,594 | $20 |
| Ezetimibe | 72 | $2,356 | $33 |
| Amlodipine Besylate | 242 | $2,308 | $10 |
| Irbesartan | 45 | $2,257 | $50 |
| Potassium Chloride | 82 | $2,106 | $26 |
| Losartan | 145 | $1,658 | $11 |
| Prasugrel | 13 | $1,467 | $113 |
| Metoprolol | 154 | $1,374 | $9 |
| Losartan-Hydrochlorothiazide | 62 | $1,257 | $20 |
| Isosorbide Mononitrate Er | 52 | $1,092 | $21 |
| Nitroglycerin | 52 | $1,043 | $20 |
| Sotalol | 34 | $1,030 | $30 |
| Lisinopril | 88 | $998 | $11 |
| Furosemide | 123 | $945 | $8 |
| Hydrochlorothiazide | 93 | $734 | $8 |
| Diltiazem | 15 | $698 | $47 |
| Diltiazem 24hr Er (Xr) | 12 | $607 | $51 |
| Isosorbide Dinitrate | 11 | $358 | $33 |
| Lisinopril-Hydrochlorothiazide | 27 | $314 | $12 |
| Famotidine | 11 | $307 | $28 |
| Propranolol | 14 | $221 | $16 |
| Atenolol | 13 | $179 | $14 |
| Pravastatin | 11 | $175 | $16 |
2022: 32 drugs
| Eliquis | 182 | $189,232 | $1,040 |
| Xarelto | 37 | $56,417 | $1,525 |
| Entresto | 14 | $17,352 | $1,239 |
| Repatha Sureclick | 18 | $13,400 | $744 |
| Praluent | 12 | $10,980 | $915 |
| Rosuvastatin | 168 | $4,417 | $26 |
| Metoprolol | 190 | $4,094 | $22 |
| Diltiazem 24hr Er (Cd) | 35 | $2,769 | $79 |
| Amiodarone | 56 | $2,558 | $46 |
| Flecainide Acetate | 41 | $2,291 | $56 |
| Valsartan | 39 | $1,851 | $47 |
| Torsemide | 48 | $1,538 | $32 |
| Atorvastatin | 99 | $1,511 | $15 |
| Carvedilol | 95 | $1,478 | $16 |
| Potassium Chloride | 46 | $1,256 | $27 |
| Amlodipine Besylate | 152 | $1,256 | $8 |
| Bisoprolol | 22 | $1,219 | $55 |
| Clopidogrel | 57 | $1,026 | $18 |
| Ezetimibe | 29 | $1,002 | $35 |
| Metoprolol | 92 | $851 | $9 |
| Spironolactone | 54 | $824 | $15 |
| Isosorbide Mononitrate Er | 40 | $802 | $20 |
| Irbesartan | 16 | $629 | $39 |
| Chlorthalidone | 17 | $578 | $34 |
| Losartan | 66 | $578 | $9 |
| Albuterol Sulfate Hfa | 11 | $481 | $44 |
| Nitroglycerin | 34 | $461 | $14 |
| Furosemide | 70 | $408 | $6 |
| Lisinopril | 67 | $380 | $6 |
| Sotalol | 12 | $380 | $32 |
| Hydrochlorothiazide | 36 | $290 | $8 |
| Pravastatin | 15 | $268 | $18 |
2021: 19 drugs
| Eliquis | 32 | $30,180 | $943 |
| Xarelto | 23 | $27,041 | $1,176 |
| Repatha Sureclick | 15 | $7,503 | $500 |
| Rosuvastatin | 51 | $2,659 | $52 |
| Metoprolol | 68 | $1,625 | $24 |
| Amiodarone | 18 | $1,472 | $82 |
| Flecainide Acetate | 12 | $855 | $71 |
| Atorvastatin | 62 | $660 | $11 |
| Carvedilol | 36 | $601 | $17 |
| Valsartan | 16 | $571 | $36 |
| Chlorthalidone | 12 | $444 | $37 |
| Potassium Chloride | 17 | $343 | $20 |
| Lisinopril | 47 | $322 | $7 |
| Amlodipine Besylate | 37 | $292 | $8 |
| Bisoprolol | 16 | $288 | $18 |
| Nitroglycerin | 15 | $231 | $15 |
| Torsemide | 11 | $175 | $16 |
| Furosemide | 20 | $148 | $7 |
| Metoprolol | 11 | $82 | $7 |
2020: 15 drugs
| Eliquis | 26 | $29,013 | $1,116 |
| Xarelto | 22 | $18,052 | $821 |
| Entresto | 11 | $6,297 | $572 |
| Metoprolol | 81 | $2,074 | $26 |
| Rosuvastatin | 35 | $1,381 | $39 |
| Atorvastatin | 56 | $731 | $13 |
| Carvedilol | 41 | $417 | $10 |
| Lisinopril | 48 | $374 | $8 |
| Bisoprolol | 19 | $328 | $17 |
| Furosemide | 35 | $260 | $7 |
| Benazepril | 13 | $220 | $17 |
| Amlodipine Besylate | 25 | $146 | $6 |
| Torsemide | 17 | $132 | $8 |
| Losartan | 11 | $105 | $10 |
| Clopidogrel | 15 | $64 | $4 |
2019: 13 drugs
| Eliquis | 32 | $26,770 | $837 |
| Xarelto | 18 | $13,912 | $773 |
| Metoprolol | 73 | $2,459 | $34 |
| Rosuvastatin | 29 | $918 | $32 |
| Atorvastatin | 40 | $697 | $17 |
| Amiodarone | 11 | $634 | $58 |
| Bisoprolol | 22 | $376 | $17 |
| Carvedilol | 23 | $295 | $13 |
| Torsemide | 27 | $276 | $10 |
| Lisinopril | 41 | $272 | $7 |
| Nitroglycerin | 21 | $215 | $10 |
| Losartan | 20 | $169 | $8 |
| Furosemide | 20 | $148 | $7 |
2018: 3 drugs
| Eliquis | 13 | $6,867 | $528 |
| Metoprolol | 19 | $473 | $25 |
| Torsemide | 13 | $87 | $7 |
Money from drug and device companies
$518 in 2025
| 2025 | 14 | 19 | None | $518 |
| 2024 | 13 | 36 | None | $852 |
| 2023 | 15 | 43 | None | $1,041 |
| 2022 | 8 | 29 | None | $589 |
| 2021 | 6 | 26 | None | $1,189 |
| 2020 | 9 | 17 | None | $613 |
| 2019 | 13 | 44 | None | $1,313 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbott Laboratories | Aveir | $208 | 3 payments
|
| Amgen | Repatha | $43 | 2 payments
|
| Alnylam Pharmaceuticals | Amvuttra | $35 | 2 payments
|
| Boston Scientific | General - Brady | $33 | 2 payments
|
| Chiesi USA | Cleviprex | $29 | 1 payment
|
| Exact Sciences | Cologuard Collection Kit | $28 | 1 payment
|
See all 19 published payments
| BridgeBio Pharma | Meals · 2025-12-31 | Attruby | $15 |
| Amgen | Meals · 2025-12-15 | Repatha | $22 |
| Boston Scientific | Meals · 2025-12-04 | Cds Broad Portfolio Offering | $16 |
| Boston Scientific | Meals · 2025-11-07 | General - Brady | $17 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-24 | Eliquis | $24 |
| Pfizer | Meals · 2025-10-11 | Eliquis | $16 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-09-18 | Lifevest | $17 |
| Amgen | Meals · 2025-09-04 | Repatha | $21 |
| Abbott Laboratories | Meals · 2025-08-25 | Aveir | $18 |
| Abbott Laboratories | Meals · 2025-06-11 | Aveir | $24 |
| Alnylam Pharmaceuticals | Meals · 2025-05-28 | Amvuttra | $18 |
| Chiesi USA | Meals · 2025-05-14 | Cleviprex | $29 |
| Novo Nordisk | Meals · 2025-05-13 | Wegovy | $17 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-12 | Lokelma | $15 |
| Exact Sciences | Meals · 2025-04-23 | Cologuard Collection Kit | $28 |
| Abbott Laboratories | Meals · 2025-04-03 | Aveir | $166 |
| Merck Sharp & Dohme | Meals · 2025-03-26 | Verquvo | $16 |
| Alnylam Pharmaceuticals | Meals · 2025-02-17 | Amvuttra | $17 |
| Novartis Pharmaceuticals | Meals · 2025-02-13 | Leqvio | $23 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $852
| Boston Scientific | Synergy | $261 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $154 | 8 payments
|
| Inari Medical | Flowtriever Catheter, S | $97 | 1 payment
|
| Amgen | Repatha | $78 | 4 payments
|
| Novo Nordisk | Wegovy | $60 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $46 | 2 payments
|
| Alnylam Pharmaceuticals | Amvuttra | $30 | 2 payments
|
| Celgene | Eliquis | $27 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $24 | 1 payment
|
| Phathom Pharmaceuticals | Voquezna | $22 | 1 payment
|
| Novartis Pharmaceuticals | Entresto | $20 | 1 payment
|
| Medtronic | Micra | $19 | 1 payment
|
| Pfizer | Eliquis | $14 | 1 payment
|
2023: $1,041
| Boston Scientific | Ilab Ultrasound Imaging System | $241 | 9 payments
|
| Abbott Laboratories | Assurity | $136 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $98 | 6 payments
|
| Medtronic | Attain Command + Surevalve | $94 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $90 | 4 payments
|
| Novartis Pharmaceuticals | Leqvio | $88 | 5 payments
|
| Celgene | Eliquis | $59 | 3 payments
|
| Lexicon Pharmaceuticals | Inpefa | $51 | 3 payments
|
| Merck Sharp & Dohme | Verquvo | $50 | 2 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $37 | 3 payments
|
| Alnylam Pharmaceuticals | Onpattro | $34 | 2 payments
|
| Pfizer | Eliquis | $19 | 1 payment
|
| Amgen | Repatha | $16 | 1 payment
|
| Biotronik | Amvia Edge | $16 | 1 payment
|
| Kiniksa Pharmaceuticals | Arcalyst | $14 | 1 payment
|
2022: $589
| Boston Scientific | Synergy | $328 | 11 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $74 | 7 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $52 | 3 payments
|
| Amgen | Repatha | $50 | 3 payments
|
| Biotronik | Edora 8 Dr-T | $39 | 2 payments
|
| Janssen Pharmaceuticals | Xarelto | $17 | 1 payment
|
| Medtronic | Selectsecure | $16 | 1 payment
|
| Impulse Dynamics (USA) | Optimizer | $14 | 1 payment
|
2021: $1,189
| Boston Scientific | Synergy | $621 | 11 payments
|
| Biotronik | Biomonitor | $268 | 6 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $185 | 5 payments
|
| HeartFlow | Ffrct | $62 | 1 payment
|
| Shockwave Medical | Vascular Lithotripsy | $32 | 2 payments
|
| Abbott Laboratories | Confirm Rx | $21 | 1 payment
|
2020: $613
| Boston Scientific | Resonate | $276 | 4 payments
|
| Janssen Pharmaceuticals | Xarelto | $104 | 2 payments
|
| Biotronik | None | $93 | 3 payments
|
| Amgen | Repatha | $47 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $34 | 2 payments
|
| Pfizer | Eliquis | $19 | 1 payment
|
| Sanofi-Aventis U.S. | Multaq | $17 | 1 payment
|
| Chiesi USA | Kengreal 50mg/10ml L | $15 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $8 | 1 payment
|
2019: $1,313
| Boston Scientific | Synergy | $303 | 5 payments
|
| Amgen | Repatha | $205 | 9 payments
|
| Biotronik | None | $190 | 4 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $128 | 3 payments
|
| Janssen Pharmaceuticals | Xarelto | $115 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $96 | 7 payments
|
| Pfizer | Eliquis | $69 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $59 | 4 payments
|
| Sanofi-Aventis U.S. | Multaq | $39 | 2 payments
|
| Regeneron Healthcare Solutions | Praluent | $37 | 2 payments
|
| Chiesi USA | Cleviprex | $28 | 2 payments
|
| Novartis Pharmaceuticals | Entresto | $25 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Pradaxa | $21 | 1 payment
|
Professional record
- NPI
- 1033503388
- Licence
- CA A144796
- Trained
- University of Washington School of Medicine, 2015
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Cardiology (207RC0000X)
- Mailing address
- 4860 Y St Ste 200, Sacramento, CA, 95817
- NPI first listed
- 2015-03-25
- NPI last updated
- 2018-10-18
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr, Stanford, CA, 94305